Cargando…
The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review
Since their discovery immune checkpoint inhibitors (ICI) have dramatically changed the treatment landscape for many cancers. In addition to their efficacy they are generally well tolerated, however, they have led to a new range of immune-related adverse events (irAEs) including pneumonitis. While no...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264318/ https://www.ncbi.nlm.nih.gov/pubmed/34295675 http://dx.doi.org/10.21037/tlcr-20-806 |